Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Calvo

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Vaccines|August 29, 2024
Immunogenicity and Safety of a Quadrivalent Influenza Vaccine in Population Aged 3 Years and Older in Chile and the Philippines: A Phase 3, Non-Inferiority, Double-Blind, Randomized Controlled Clinical TrialWanqi Yang, Pablo A González, Qianqian Xin, et al.
Antiviral Therapy|October 16, 2014
A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome caused by Andes virusPablo A Vial, Francisca Valdivieso, Mario Calvo, et al.
Frontiers in Immunology|June 22, 2026
Polyfunctional antibody signature defines protection in Andes hantavirus survivalFelipe Bravo, Tybbysay P Salinas, Camila Kossack, et al.
The Lancet. Infectious Diseases|April 6, 2024
Viral shedding and viraemia of Andes virus during acute hantavirus infection: a prospective studyMarcela Ferrés, Constanza Martínez-Valdebenito, Carolina Henriquez, et al.
Frontiers in Immunology|February 24, 2022
Sustained Antibody-Dependent NK Cell Functions in Mild COVID-19 Outpatients During ConvalescenceFrancisco Fuentes-Villalobos, Jose L Garrido, Matías A Medina, et al.
Vaccines|October 28, 2023
Different Safety Pattern of an Inactivated SARS-CoV-2 Vaccine (CoronaVac<sup>®</sup>) According to Age Group in a Pediatric Population from 3 to 17 Years Old, in an Open-Label Study in ChileNicole Le Corre, Katia Abarca, Patricio Astudillo, et al.
Revista Alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)|June 11, 2014
[ARIA (Allergic Rhinitis and its Impact on Asthma). Achievements in 10 years and future needs in Latin America]Carlos E Baena-Cagnani, Mario Sánchez-Borges, Mario E Zernotti, et al.
Nature Communications|December 7, 2025
Influenza vaccines promote humoral and cellular immune responses: a randomized, double-blind, phase 3 trialLinmar Rodríguez-Guilarte, Constanza Méndez, Antonia Reyes, et al.
Mbio|November 16, 2022
Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in ChildrenJorge A Soto, Felipe Melo-González, Cristián Gutierrez-Vera, et al.
Allergy|April 18, 2026
Availability and Costs of Allergic Rhinitis Treatments Across the World: A Survey of ARIA ExpertsMaria Clara Urbano, Rafael José Vieira, Yi-Kui Xiang, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Vaccines|August 29, 2024
Immunogenicity and Safety of a Quadrivalent Influenza Vaccine in Population Aged 3 Years and Older in Chile and the Philippines: A Phase 3, Non-Inferiority, Double-Blind, Randomized Controlled Clinical TrialWanqi Yang, Pablo A González, Qianqian Xin, et al.
Antiviral Therapy|October 16, 2014
A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome caused by Andes virusPablo A Vial, Francisca Valdivieso, Mario Calvo, et al.
Frontiers in Immunology|June 22, 2026
Polyfunctional antibody signature defines protection in Andes hantavirus survivalFelipe Bravo, Tybbysay P Salinas, Camila Kossack, et al.
The Lancet. Infectious Diseases|April 6, 2024
Viral shedding and viraemia of Andes virus during acute hantavirus infection: a prospective studyMarcela Ferrés, Constanza Martínez-Valdebenito, Carolina Henriquez, et al.
Frontiers in Immunology|February 24, 2022
Sustained Antibody-Dependent NK Cell Functions in Mild COVID-19 Outpatients During ConvalescenceFrancisco Fuentes-Villalobos, Jose L Garrido, Matías A Medina, et al.
Vaccines|October 28, 2023
Different Safety Pattern of an Inactivated SARS-CoV-2 Vaccine (CoronaVac<sup>®</sup>) According to Age Group in a Pediatric Population from 3 to 17 Years Old, in an Open-Label Study in ChileNicole Le Corre, Katia Abarca, Patricio Astudillo, et al.
Revista Alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)|June 11, 2014
[ARIA (Allergic Rhinitis and its Impact on Asthma). Achievements in 10 years and future needs in Latin America]Carlos E Baena-Cagnani, Mario Sánchez-Borges, Mario E Zernotti, et al.
Nature Communications|December 7, 2025
Influenza vaccines promote humoral and cellular immune responses: a randomized, double-blind, phase 3 trialLinmar Rodríguez-Guilarte, Constanza Méndez, Antonia Reyes, et al.
Mbio|November 16, 2022
Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in ChildrenJorge A Soto, Felipe Melo-González, Cristián Gutierrez-Vera, et al.
Allergy|April 18, 2026
Availability and Costs of Allergic Rhinitis Treatments Across the World: A Survey of ARIA ExpertsMaria Clara Urbano, Rafael José Vieira, Yi-Kui Xiang, et al.
Pageof 6